Neil K. Taunk

Neil K. Taunk

Auto-generated profile, based on publicly available information

Neil K. Taunk

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
JTJacob Trotter
Jacob Trotter
APAustin R. Pantel
Austin R. Pantel
BTBoon-Keng Kevin Teo
Boon-Keng Kevin Teo
FEFreddy E. Escorcia
Freddy E. Escorcia
TLTaoran Li
Taoran Li
NTNeil K. Taunk
Neil K. Taunk
Positron emission tomography (PET)/computed tomography (CT) has become a critical tool in clinical oncology with an expanding role in guiding radiation treatment planning. As its application and availability grows, it is increasingly important for practicing radiation oncologists to have a comprehensive understanding of how molecular imaging can be incorporated into radiation planning and recognize its potential limitations and pitfalls. The purpose of this article is to review the major approved positron-emitting radiopharmaceuticals clinically being used today along with the methods used for their integration into radiation therapy including methods of image registration, target delineation, and emerging PET-guided protocols such as biologically-guided radiation therapy and PET-adaptive therapy. A review approach was utilized using collective information from a broad review of the existing scientific literature sourced from PubMed search with relevant keywords and input from a multidisciplinary team of experts in medical physics, radiation treatment planning, nuclear medicine, and radiation therapy. A number of radiotracers imaging various targets and metabolic pathways of cancer are now commercially available. PET/CT data can be incorporated into radiation treatment planning through cognitive fusion, rigid registration, deformable registration, or PET/CT simulation techniques. PET imaging provides a number of benefits to radiation planning including improved identification and delineation of the radiation targets from normal tissue, potential automation of target delineation, reduction of intra- and inter-observer variability, and identification of tumor subvolumes at high risk for treatment failure which may benefit from dose intensification or adaptive protocols. However, PET/CT imaging has a number of technical and biologic limitations that must be understood when guiding radiation treatment. For PET guided radiation planning to be successful, collaboration between radiation oncologists, nuclear medicine physicians, and medical physics is essential, as well as the development and adherence to strict PET-radiation planning protocols. When performed properly, PET-based radiation planning can reduce treatment volumes, reduce treatment variability, improve patient and target selection, and potentially enhance the therapeutic ratio accessing precision medicine in radiation therapy.

1 May 2024 in The Cancer Journal
Verified
Journal Article
Closed access
NTNeil K. Md Taunk
Neil K. Md Taunk
FEFreddy E. Escorcia
Freddy E. Escorcia
JLJason S. Lewis
Jason S. Lewis
LBLisa Bodei
Lisa Bodei
Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies, peptides, or small molecules has expanded the scope of radiopharmaceutical therapy, enabling precise and effective cancer treatment for an increasing number of tumor types. Alpha emitters, characterized by their high linear energy transfer and short path length, offer unique advantages in targeted therapy due to their potent cytotoxicity against cancer cells while sparing healthy tissues. This article reviews recent advancements in identifying novel targets for radiopharmaceutical therapy and applications in utilizing α-emitters for targeted treatment.

25 September 2025 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
APAbigail Pepin
Abigail Pepin
ADAbigail Doucette
Abigail Doucette
NVNeha Vapiwala
Neha Vapiwala
VNVivek K. Narayan
Vivek K. Narayan
STSamuel U. Takvorian
Samuel U. Takvorian
NTNeil K. Taunk
Neil K. Taunk
The VISION trial of 177Lu-PSMA-617 (LuPSMA) demonstrated improved overall survival in patients with metastatic castration-resistant prostate cancer when compared with the best standard of care. The practice patterns for and safety of the combination of external beam radiotherapy (EBRT) and LuPSMA in the real-world setting are unknown. Here, we characterize the toxicities and efficacy of the combination of EBRT and LuPSMA among patients with metastatic castration-resistant prostate cancer. Methods: The records of all patients treated with LuPSMA at an urban academic institution between 2022 and 2024 were retrospectively extracted from the electronic medical record. Patients were stratified on the basis of their receipt of EBRT. Treatment characteristics of both systemic therapy and EBRT were extracted. Provider-reported toxicities after LuPSMA and EBRT were assessed. Overall survival was assessed using Kaplan–Meier analysis. Results: The records of 113 patients were included in the analysis, including 92 patients who received EBRT and LuPSMA and 21 patients who received LuPSMA alone. The median age was 71.5 and 75 y in the combination therapy and the monotherapy groups, respectively. All patients were heavily pretreated. There were significantly higher rates of prior taxane-based chemotherapy in the combination group compared with those who received LuPSMA alone (92.4% vs. 76.2%; P = 0.045). In total, 207 EBRT courses were delivered among 92 patients. Of these courses, 164 (79.2%) were administered before the start of LuPSMA and 15 (7.2%) occurred between cycles of LuPSMA. Thirty-six patients (39.1%) received periconcurrent LuPSMA (i.e., within 3 mo of receiving EBRT). Most EBRT courses were palliative in intent. There were no significant differences in fatigue, dry eye, and cytopenias after administration of LuPSMA alone compared with periconcurrent LuPSMA and EBRT. There were higher rates of thrombocytopenia (any grade) in patients who received EBRT within 3 mo of LuPSMA relative to those who received EBRT more than 3 mo before LuPSMA (60.6% vs. 34.0%; P = 0.03). The median follow-up was 6.8 mo, during which there were no differences in overall survival between patients treated with prior EBRT relative to those who had never received EBRT (P = 0.10). There were also no differences in overall survival in patients treated with EBRT within 3 mo of LuPSMA relative to those who had never received EBRT (P = 0.10). Conclusion: Receipt of EBRT during or within 3 mo of LuPSMA was not associated with increased toxicity compared with LuPSMA alone and was not associated with receiving fewer cycles of LuPSMA. There were no differences with respect to overall survival between patients who received prior EBRT or EBRT within 3 mo and those who had never received EBRT. Treatment with EBRT in combination with LuPSMA can be incorporated as needed for primarily palliative purposes. Visual Abstract

19 February 2026 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
APAbigail Pepin
Abigail Pepin
ADAbigail Doucette
Abigail Doucette
VNVivek K. Narayan
Vivek K. Narayan
KMKara N. Maxwell
Kara N. Maxwell
STSamuel U. Takvorian
Samuel U. Takvorian
NTNeil K. Taunk
Neil K. Taunk
Genomic alterations are common in metastatic castration-resistant prostate cancer (mCRPC), but limited data exist on the response to 177Lu-PSMA-617 (LuPSMA) in patients with these aberrations. We aimed to characterize oncologic outcomes of patients with mCRPC and germline or somatic aberrations after treatment with LuPSMA. Methods: The medical record was surveyed for all patients with mCRPC treated with LuPSMA between October 2022 and October 2024. All patients who had received at least 1 cycle of LuPSMA and underwent either germline or somatic testing were included. Results: Seventy-two patients were included. Patients with TP53/PTEN/RB1 mutations demonstrated inferior overall survival, even after adjustment for age and race. TP53/PTEN/RB1, BRCA1/2, and CHEK2/PALB2/ATM were not associated with inferior progression-free survival. No individual mutation was significantly associated with changes in the percentage decline in prostate-specific antigen levels from baseline. Conclusion:TP53, PTEN, and RB1 mutations were linked to inferior overall survival in LuPSMA-treated patients and may serve as prognostic biomarkers. Prospective validation is required to establish their predictive value.

10 December 2022 in Practical Radiation Oncology
Verified
Journal Article
Closed access
NTNeil K. Taunk
Neil K. Taunk
EFEmma C. Fields
Emma C. Fields
JBJeffrey V. Brower
Jeffrey V. Brower